Novartis shares plunge after trial misses primary goal
Novartis said an experimental neuromuscular medicine missed the primary goal in a late-stage clinical trial. Shares slid 10% shortly after the opening bell Tuesday.
Novartis shares plunged after the Swiss drugmaker said an experimental neuromuscular medicine missed the primary goal in a late-stage clinical trial, the latest setback in its search for new growth drivers. Shares in Novartis slid 10% shortly after the opening bell Tuesday.